Cytotoxic and genotoxic potential of dopamine

Journal of Neuroscience Research

Volumn 55, Issue 6, 1999, Pages 659-665

  Stokes, Alan H ^a   Hastings, Teresa G ^b   Vrana, Kent E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Dopamine quinone; Reactive oxygen species

Indexed keywords

DOPAMINE; QUINONE DERIVATIVE; REACTIVE OXYGEN METABOLITE;

APOPTOSIS; CELL DEATH; CYTOTOXICITY; DEGENERATIVE DISEASE; DOPAMINE METABOLISM; ENZYME ACTIVITY; GENOTOXICITY; HUMAN; NEUROTOXICITY; NEUROTRANSMISSION; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; SHORT SURVEY;

ANIMALS; BRAIN; BRAIN ISCHEMIA; CYTOTOXINS; DOPAMINE; HUMANS; MUTAGENS; NERVE DEGENERATION; OXIDATION-REDUCTION; PARKINSON DISEASE;

EID: 0033559008     PISSN: 03604012     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-4547(19990315)55:6<659::AID-JNR1>3.0.CO;2-C     Document Type: Short Survey

References (70)

1. Barbeau A. 1984. Manganese and extrapyramidal disorders (a critical review and tribute to Dr. George C. Cotzias). Neurotoxicology 5:13-35.
2. Berman SB, Hastings TG. 1997a. Inhibition of glutamate transport in synaptosomes by dopamine oxidation and reactive oxygen species. J Neurochem 69:1185-1195.
3. Berman SB, Hastings TG. 1997b. Effects of dopamine oxidation products on mitochondrial function: implications for Parkinson's disease. Soc Neurosci Abstr. 23:1370.
4. Berman SB, Zigmond MJ, Hastings TG. 1996. Modification of dopamine transporter function: effect of reactive oxygen species and dopamine. J Neurochem 67:593-600.
5. Buttke TM, Sandstrom PA. 1994. Oxidative stress as a mediator of apoptosis. Immunol Today 15:7-10.
6. Dexter DT, Wells FR, Lees AJ, Agid F, Agid Y, Jenner P, Marsden CD. 1989. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem 52:1830-1836.
7. Donaldson J, McGregor D, LaBella F. 1982. Manganese neurotoxicity: a model for free radical mediated neurodegeneration? Can J Phsiol Pharmacol 60:1398-1405.
8. Filloux F, Townsend JJ. 1993. Pre- and postsynaptic neurotoxic effects of dopamine demonstrated by intrastriatal injection. Exp Neurol 119:79-88.
9. Foley JM, Baxter D. 1958. On the nature of pigment granule in the cells of the locus coeruleus and substantia nigra. J Neuropathol Exp Neurol 17:586-589.
10. Foppoli C, Coccia R, Cini C, Rosei MA. 1997. Catecholamines oxidation by xanthine oxidase. Biochim et Biophys Acta 1334:200-206.
11. Fornstedt B, Carlsson A. 1989. A marked rise in 5-S-cysteinyldopamine levels in guinea-pig striatum following reserpine treatment. J Neural Trans 76:155-161.
12. Fornstedt B, Carlsson A. 1991. Vitamin C deficiency facilitates 5-S-cysteinyldopamine formation in guinea-pig striatum. J Neurochem 56:407-414.
13. Fornstedt B, Rosengren E, Carlsson A. 1986. Occurrence and distribution of 5-cysteinyl derivatives of dopamine, DOPA and DOPAC in the brains of eight mammalian species. Neuropharmacology 25:451-454.
14. Fornstedt B, Pileblad E, Carlsson A. 1990. In vivo autoxidation of dopamine in guinea-pig striatum increases with age. J Neurochem 55:655-659.
15. Gabbay M, Tauber M, Porat S, Simantov R. 1996. Selective role of glutathione in protecting human neuronal cells from dopamine-induced apoptosis. Neuropharmacology 35:571-578.
16. Gotz ME, Kunig G, Reiderer P, Youdim MB. 1994. Oxidative stress: free radical production in neural degeneration. Pharmacol Ther 63:37-122.
17. Graham DG. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
18. Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF. 1978. Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward c 1300 neuroblastoma cells in vitro. Mol Pharmacol 14:644-653.
19. Halliwell B. 1992. Reactive oxygen species and the central nervous system. J Neurochem 59:1609-1623.
20. Halliwell B, Gutteridge JMC. 1984. Oxygen toxicity, oxygen radicals, transition metals and disease. J Biochem 219:1-14.
21. Hastings TG. 1995. Enzymatic oxidation of dopamine: role of prostaglandin H synthase. J Neurochem 64:919-924.
22. 3H] dopamine: impact of ascorbic acid and glutathione. J Neurochem 63:1126-1132.
23. Hastings TG, Lewis DA, Zigmond MJ. 1996. Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci USA 93:1956-1961.
24. Hoyt KR, Reynolds IJ, Hastings TG. 1997. Mechanisms of dopamine-induced cell death in cultured rat forebrain neurons: interactions with and differences from glutamate-induced cell death. Exp Neurol 143:269-281.
25. Kato T, Ito S, Fujita K. 1986. Tyrosinase-catalyzed binding of 3,4-dihydroxyphenylalanine with proteins through the sulfhydryl group. Biochim Biophys Acta 881:415-421.
26. Korner A, Pawelek J, 1982. Mammalian tyrosinase catalyzes three reactions in the biosynthesis of melanin. Science 217:1163-1165.
27. Korytowski W, Sarna T, Kalyanaraman B, Sealy RC. 1987. Tyrosinase-catalyzed oxidation of dopa and related catechol(amine)s: a kinetic electron spin resonance investigation using spinstabilization and spin-label oximetry. Biochim et Biophy Acta 924:383-392.
28. Kuhn DM, Arthur RA Jr. 1998. Dopamine inactivates tryptophan hydroxylase and forms a redox-cycling quinoprotein: possible endogenous toxin to serotonin neurons. J Neurosci 18:7111-7117.
29. LaVoie MJ, Hastings TG. 1998. Dopamine quinone formation and protein modification associated with striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci (in press).
30. Lawley PD, Phillips DH. 1996. DNA adducts from chemotherapeutic agents. Mut Res 355:13-40.
31. Levay G, Bodell WJ. 1993. Detection of dopamine-DNA adducts: potential role in parkinson's disease. Carcinogenesis 14:1241-1245.
32. Luo Y, Umegaki H, Wang X, Abe R, Roth GS. 1998. Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J Biol Chem 273:3756-3764.
33. Maker HS, Weiss C, Silides DJ, Cohen G. 1981. Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates. J Neurochem 36:589-593.
34. Masserano JM, Gong L, Kulaga H, Baker I, Wyatt RJ. 1996. Dopamine induces apoptotic cell death of a catecholaminergic cell line derived from the central nervous system. Mol Pharmacol 50:1309-1315.
35. Mattamal MB, Strong R, White VE, Hsu F. 1994. Characterization of peroxidative oxidation products of dopamine by mass spectrometry. J Chromatog B 658:21-30.
36. Mattamal MB, Strong R, Lakshmi VM, Chung HD, Stephenson AH. 1995. Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J Neurochem 64:1645-1654.
37. Michel PP, Hefti F. 1990. Toxicity of 6-hydroxydopamine and dopamine for dopaminergic neurons in culture. J Neurosci Res 26:428-435.
38. Miranda M, Botti D, Bonfigli A, Ventura T, Arcadi A. 1984. Tyrosinaselike activity in normal human substantia nigra. Gen Pharmacol 15:541-544.
39. Moldeus P, Nordenskjold M, Bolcsfoldi G, Eiche A, Haglund U, Lambert B. 1983. Genetic toxicity of dopamine. Mut Res 124:9-24.
40. Montine TJ, Picklo MJ, Amarnath V, Whetsell WO Jr, Graham DG. 1997. Neurotoxicity of endogenous cysteinylcatechols. Exp Neurol 148:26-33.
41. 2 oxidation of dopamine. J Med Chem 38:917-922.
42. Nappi AJ, Vass E, Prota G, Memoli S. 1995. The effects of hydroxylradical attack on dopa, dopamine, 6-hydroxydopa, and 6-hydroxydopamine. Pigment Cell Res 8:283-293.
43. Offen D, Ziv I, Sternin H, Melamed E, Hochman A. 1996. Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol 141:32-39.
44. Offen D, Ziv I, Panet H, Wasserman L, Stein R, Melamed E, Barzilai A. 1997. Dopamine-induced apoptosis is inhibited in PC12 cells expressing Bcl-2. Cell Mol Neurobiol 17:289-304.
45. Perry TL, Godin DV, Hansen S. 1982. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33:305-310.
46. Rabinovic AD, Hastings TG. 1998. Role of endogenous glutathione in the oxidation of dopamine. J Neurochem 71:2071-2078.
47. Rabinovic AD, Zigmond MJ, Hastings TG. 1996. Early indices of oxidative stress: immediate response to neurotoxic levels of endogenous dopamine. Soc Neurosci Abstr 22:221.
48. Raper HS. 1928. The aerobic oxidases. Physiol Rev 8:245-282.
49. Reiderer P, Sofic E, Rausch W-D, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH. 1989. Transition metals, ferritin, glutathione, and ascorbic acid in Parkinsonian brains. J Neurochem 52:515-520.
50. Rodriguez-Lopez JN, Varon R, Garcia-Canovas F. 1993. Oxidation of 6-hydroxydopamine catalyzed by tyrosinase. Int J Biochem 25:1175-1182.
51. Rosei MA, Blarzino C, Foppoli C, Mosca L, Coccia R. 1994. Lipoxygenase-catalyzed oxidation of catecholamines. Biochem Biophys Res Comm 200:344-350.
52. Rosenberg PA. 1988. Catecholamine toxicity in cerebral cortex in dissociated cell culture. J Neurosci 8:2887-2894.
53. Sanchez-Ramos JR, Overvik E, Ames BN. 1994. A Marker of oxyradical-mediated DNA damage (8-hydroxy-2′deoxyguanosine) is increased in nigro-striatum of Parkinson's disease brain. Neurodegeneration 3:197-204.
54. Sanderson BJS, Shield AJ. 1996. Mutagenic damage to mammalian cells by therapeutic alkylating agents. Mut Res 355:41-57.
55. Sian J, Dexter DT, Lees AJ, Daniel S, Jenner P, Marsden CD. 1994. Glutathione-related disease in brain in Parkinson's disease. Ann Neurol 36:356-361.
56. Simantov R, Blinder E, Ratovitski T, Tauber M, Gabbay M, Porat S. 1996. Dopamine-induced apoptosis in human neuronal cells: inhibition by nucleic acids antisense to the dopamine transporter. Neuroscience 74:39-50.
57. Spencer JPE, Jenner P, Halliwell B. 1995. Superoxide-dependent depletion of reduced glutathione by L-DOPA and dopamine. Relevance to Parkinson's disease. NeuroReport 6:1480-1484.
58. Spencer JPE, Jenner P, Daniel SE, Lees AJ, Marsden CD, Halliwell B. 1998. Conjugates of catecholamines with cysteine and GSH in Parkinson's disease: Possible mechanisms of formation involving reactive oxygen species. J Neurochem 71:2112-2122.
59. Stokes AH, Brown BG, Lee CK, Doolittle DJ, Vrana KE. 1996. Tyrosinase enhances the covalent modification of DNA by dopamine. Mol Brain Res 42:167-170.
60. Tse DCS, McCreery RL, Adams RN. 1976. Potential oxidative pathways of brain catecholamines. J Med Chem 19:37-40.
61. Walkinshaw G, Waters C. 1995. Induction of apoptosis in catecholaminergic PC12 cells by L-DOPA: implications for the treatment of Parkinson's disease. J Clin Invest 95:2458-2464.
62. Wick MM. 1978. Dopamine: a novel antitumor agent active against B-16 melanoma in vivo. J Invest Dermatol 71:163-164.
63. Wick MM. 1980. Levodopa and dopamine analogs as DNA polymerase inhibitors and antitumor agents in human melanoma. Cancer Res 40:1414-1418.
64. Wick MM, Byers L, Frei F. 1977. L-DOPA: selective toxicity for melanoma cells in vitro. Science 197:468-469.
65. Xu Y, Stokes AH, Freeman WM, Kumer SC, Vogt BA, Vrana KE. 1997. Tyrosinase mRNA is expressed in human substantia nigra. Mol Brain Res 45:159-162.
66. Xu Y, Stokes AH, Roskoski R Jr, Vrana KE. 1998. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J Neurosci Res 54:691-697.
67. Youdim MBH. 1988. Iron in the brain: implications for Parkinson's and Alzheimer's diseases. Mount Sinai J Med 55:97-101.
68. Zhang F, Dryhurst G. 1994. Effects of L-cysteine on the oxidation chemistry of dopamine: new reaction pathways of potential relevance to idiopathic Parkinson's disease. J Med Chem 37:1084-1098.
69. Ziv I, Melamed E, Nardi N, Luria D, Achiron A, Offen D, Barzilai A. 1994. Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons - a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett 170:136-140.
70. Ziv I, Barzilai A, Offen D, Stein R, Achiron A, Melamed E. 1996. Dopamine-induced, genotoxic activation of programmed cell death: a role in nigrostriatal neuronal degeneration in Parkinson's disease? Adv Neurol 69:229-233.